It has been reported that the level of soluble EPOR may contribute to erythropoietin resistance in end stage renal disease, and that its production may be mediated by pro-inflammatory cytokines such as TNF-α and IL-6 (122), indicating soluble EPOR as a potential biomarker of cell injury. This evidence concerns the gene EPOR and chronic kidney disease.